Close Menu

NEW YORK – Illumina said this week that it was notified of an unsolicited "mini-tender offer" by TRC Capital to purchase up to 500,000 shares of Illumina common stock at a price of $268.80 per share in cash. Illumina noted that the offer is subject to a number of conditions, including TRC's ability to obtain sufficient funding, and that the offer will expire at 12:01 am on Oct. 3.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.